Crosscheck

Your medical. Crosschecked.

Infections

Terbinafine

Antifungal Agent
Other names: Lamisil

FAA guidance

Acceptable with conditions.

Wait

48 hours

after the first dose of the oral form

There is more to this wait.

Source: FAA, MedGuide (FAA Office of Aerospace Medicine medication reference). FAA date 1 October 2026. Checked by Crosscheck 14 October 2026

The FAA's MedGuide lists terbinafine (Lamisil) as allowed, for fungal infections, with a wait of 48 hours after the first dose if it is the oral form and none if it is the topical form, and none after later doses or after the final dose, used as prescribed.

Track your medications
More detail: terbinafineThe rest of Crosscheck's reading, in plain wordsOpen

Wait

  • none for the topical form

The MedGuide defines allowed as acceptable for use while performing flight or safety-related duties, provided the condition is stable/aeromedically acceptable and no adverse side effects are present, and says wait times are not determined solely by the medication: an extended observation period may be required to verify clinical stability of the condition.

  • terbinafine by mouth: 48 hours after the first dose: ground observation
Show the FAA's words: terbinafineThe official FAA wording: three passages, each with its document and dateOpen
FAA, MedGuide (FAA Office of Aerospace Medicine medication reference) · FAA date 1 October 2026
Generic: terbinafine
Brand Name: LamISIL [INTL]
Drug Class: Antifungal Agent
Underlying Condition: Fungal infections
Use: ALLOW
INITIAL Wait Time (after first dose): None (if topical formulation); or 48 hours (if oral formulation)
SUBSEQUENT Dose Wait Time (after each dose): None
DISCONTINUATION Wait Time (after final dose): None
Frequency Use Limit: As prescribed
FAA, MedGuide (FAA Office of Aerospace Medicine medication reference) · FAA date 1 October 2026
ALLOWED: The medication is acceptable for use while performing flight or safety-related duties, provided the condition is stable/aeromedically acceptable and no adverse side effects are present.
FAA, MedGuide (FAA Office of Aerospace Medicine medication reference) · FAA date 1 October 2026
Underlying Condition: Evaluating medication use requires considering the impact of safety of flight from both the medication and underlying condition. Wait times are not determined solely by the medication; an extended observation period may be required to verify clinical stability of the condition.
Sources and dates: terbinafineOne FAA document, with the FAA's date and when Crosscheck checked itOpen

See also

Medication guidance alone does not determine whether a pilot is medically qualified to fly. The underlying condition, dosage, side effects, medication combinations, and certification history may affect FAA eligibility.

For informational purposes only. Not legal or medical advice.